EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy

Ananna Bhadra Arna, Hardikkumar Patel, Ravi Shankar Singh, Frederick S Vizeacoumar, Anthony Kusalik, Andrew Freywald, Franco J Vizeacoumar, Yuliang Wu

Frontiers in Oncology · 26.01.2023 · 12

DOI: 10.3389/fonc.2022.1087989 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 26.01.2023. Verfasst von Ananna Bhadra Arna und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK, Canada. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DEAD/H-box helicases are implicated in virtually every aspect of RNA metabolism, including transcription, pre-mRNA splicing, ribosomes biogenesis, nuclear export, translation initiation, RNA degradation, and mRNA editing. Most of these helicases are upregulated in various cancers and mutations in some of them are associated with several malignancies. Lately, synthetic lethality (SL) and synthetic dosage lethality (SDL) approaches, where genetic interactions of cancer-related genes are exploited as therapeutic targets, are emerging as a leading area of cancer research. Several DEAD/H-box helicases, including DDX3, DDX9 (Dbp9), DDX10 (Dbp4), DDX11 (ChlR1), and DDX41 (Sacy-1), have been subjected to SL analyses in humans and different model organisms. It remains to be explored whether SDL can be utilized to identity druggable targets in DEAD/H-box helicase overexpressing cancers. In this review, we analyze gene expression data of a subset of DEAD/H-box helicases in multiple cancer types and discuss how their SL/SDL interactions can be used for therapeutic purposes. We also summarize the latest developments in clinical applications, apart from discussing some of the challenges in drug discovery in the context of targeting DEAD/H-box helicases.

Schlagwörter

Stichwörter der Autor:innen

DEAD/H-box helicasecancerdrug developmentsynthetic dosage lethalitysynthetic lethalitytherapeutic target

Autor:innen und Institutionen

  • Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK, Canada.
  • Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
  • Department of Computer Science, University of Saskatchewan, Saskatoon, SK, Canada.
  • Division of Oncology, College of Medicine, University of Saskatchewan and Saskatchewan Cancer Agency, Saskatoon, SK, Canada.

Zitieren

APA

Arna, A. B., Patel, H., Singh, R. S., Vizeacoumar, F. S., Kusalik, A., Freywald, A., Vizeacoumar, F. J., & Wu, Y. (2023). Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1087989

Vancouver

Arna AB, Patel H, Singh RS, Vizeacoumar FS, Kusalik A, Freywald A, et al. Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1087989

BibTeX
@article{Arna2023,
  author = {Arna, Ananna Bhadra and Patel, Hardikkumar and Singh, Ravi Shankar and Vizeacoumar, Frederick S and Kusalik, Anthony and Freywald, Andrew and Vizeacoumar, Franco J and Wu, Yuliang},
  title = {Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {12},
  doi = {10.3389/fonc.2022.1087989}
}
Kostenlos starten →